Assessment of safety and clinical tolerability of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients.

Trial Profile

Assessment of safety and clinical tolerability of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions
  • Sponsors ASIT biotech
  • Most Recent Events

    • 10 Aug 2017 Last checked against European Clinical Trials Database record.
    • 22 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 24 Jan 2017 Results published in an ASIT biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top